Will Smith & Nephew Gain on D-RAD SMART PACK Launch? - Analyst Blog

An image of a pen on a graph
Credit: Shutterstock photo

U.K.-based medical technology manufacturer Smith & Nephew plc ( SNN ) plans to introduce the D-RAD SMART PACK System at the ongoing American Society for Surgery of the Hand (ASSH) annual meeting in Boston. This new D-RAD SMART PACK System will be used for the fixation of fractures involving the distal radius.

The D-RAD SMART PACK System, designed to treat the most commonly plated extra-articular and intra-articular distal radius fractures, shortens the treatment process for surgeons and supporting OR staff. The system includes four different sterile single-use instrument kits and a tray of sterile packaged fasteners and templates to offset challenges that come with the use of conventional reprocessed plate and screw systems.

Each of the single-use kits consists of an anatomically contoured 4-hole volar plate and single-use instrumentation. The tray includes separately packed cortex screws, locking screws, locking pegs and single-use plate templates to assist kit selection.

Apart from saving on procedural costs, this new system can also enhance work efficiency within the hospital setting by cutting down on procedure time. No doubt, that the device is much in demand among health care providers, who are keen to capitalize on the technology to improve patient outcomes. The D-RAD system also incorporates Chart Sticks, which has the ability to record part numbers for every patient, and individually packed screws that minimize wastage by eradicating the need to discard unused screws.

Given the unique cost-efficient and up-to-date features of the D-RAD system, we can reasonably expect the system to be accretive to the company's financials, once fully available post its market launch.

Currently, Smith & Nephew carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical products industry include ICU Medical, Inc. ( ICUI ), Abaxis, Inc. ( ABAX ) and Conatus Pharmaceuticals Inc. ( CNAT ). While ICU Medical sports a Zacks Rank #1 (Strong Buy), both Abaxis and Conatus hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SMITH & NEPHEW (SNN): Free Stock Analysis Report

ABAXIS INC (ABAX): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

CONATUS PHARMA (CNAT): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More